Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631

Article Oncology

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol

J. Stutterheim et al.

Summary: The outcome of infants with KMT2A-germline acute lymphoblastic leukemia (ALL) is better than infants with KMT2A-rearranged ALL, but still inferior to non-infant ALL patients. Young age at diagnosis and low MRD levels during early treatment show favorable prognostic factors.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Letter Hematology

Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial

Erin M. Guest et al.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Janine Stutterheim et al.

Summary: MRD levels are predictive of outcomes in infant acute lymphoblastic leukemia, helping to guide treatment interventions.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol

Grigory Tsaur et al.

Summary: Detection of minimal residual disease (MRD) using fusion-gene transcript (FGT) can predict the prognosis of infants with acute lymphoblastic leukaemia (ALL) with lysine methyltransferase 2A (KMT2A) rearrangements. It helps identify which infants can be cured with conventional chemotherapy and which ones would benefit from other treatment approaches.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631

Patrick A. Brown et al.

Summary: Adding lestaurtinib did not improve event-free survival overall for infants with KMT2A-rearranged acute lymphoblastic leukemia, but patients who achieved potent FLT3 inhibition and had leukemia blasts sensitive to FLT3 inhibition ex vivo did benefit from the addition of lestaurtinib. Patient selection and pharmacodynamics-guided dose escalation may enhance the efficacy of FLT3 inhibition for this subtype of infant ALL.

LEUKEMIA (2021)

Add to Collection

Article Hematology